CV
Mark Lubberink

Current position

Professor of molecular imaging physics (May 2020 –)
Department of Surgical Sciences / Radiology & Nuclear Medicine, Uppsala University, Uppsala, Sweden
Main research interest: quantitative PET methodology; development of methods for automated analysis to enable clinical use of true functional imaging with PET; image-based dosimetry of targeted therapy. Combined with a 30% appointment as senior medical physicist and head of diagnostic medical physics at Uppsala University Hospital.

Co-founder and chief scientific officer, MedTrace Pharma A/S (2018 –)
MedTrace makes PET perfusion imaging with ^{15}O-water clinically available using the MT-100 point-of-care chemistry system and the aQuant software for automated analysis and visualisation.

Previous positions

2010-2020	Senior medical physicist Department of Medical Physics, Uppsala University Hospital *Head of diagnostic medical physics 2015-2020* *Professor (adj. 20%) of molecular imaging 2015-2020* *Head of nuclear medicine physics 2012-2015*
2005-2010	Medical physicist, Department of Nuclear medicine & PET research VU university medical centre, Amsterdam
2003-2005	Post-doctoral researcher, Department of Nuclear medicine & PET research VU university medical centre, Amsterdam
2002-2003	Research scientist, clinical physicist Uppsala Imanet AB, Uppsala
2001-2002	Physicist, Department of Nuclear Medicine Uppsala University Hospital

Education

2005	Certified medical physicist in nuclear medicine, Dutch Society of Clinical Physics (renewed 2010, 2015)
2003	Certified medical physicist, Swedish National Board of Health and Welfare
2001	PhD, Medical radiation physics, Uppsala University
1997	MSc, Technical physics, Eindhoven University of Technology, Eindhoven, The Netherlands

Publications

188 publications (Pubmed); H-index 51
Key publications:

1. Ilan E, …, Lubberink M. Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using ^{68}Ga-DOTATOC and ^{68}Ga-DOTATATE. J Nucl Med 61:217-221, 2020
2. Lindström E, …, Lubberink M, Evaluation of penalized-likelihood estimation reconstruction on a digital time-of-flight PET/CT scanner for ^{18}F-FDG whole body examinations. J Nucl Med 59:1152-1158, 2018
3. Johansson E, Lubberink M *et al*. Whole-body imaging of tissue-specific insulin sensitivity and body composition by using an integrated PET/MR system: a feasibility study. Radiology 286:271-278, 2018
4. Sörensen J, …, Lubberink M *et al*. Measuring HER2-receptor expression in metastatic breast cancer using [^{68}Ga]ABY-025 affibody PET/CT. Theranostics 6:262, 2016
5. Jonasson M, …, Lubberink M. Tracer kinetic analysis of (*S*)-^{18}F-THK5117 as a PET tracer for assessing tau pathology. J Nucl Med 57:574-581, 2016
6. Ilan E, …, Lubberink M. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med 56:177-182, 2015
7. Antoni G, Lubberink M *et al*. In-vivo visualization of amyloid deposits in the heart with [^{11}C]PIB and PET. J Nucl Med 54:213-220, 2013
8. Sandström M, …, Lubberink M. Comparative biodistribution and radiation dosimetry of ^{68}Ga-DOTATOC and ^{68}Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med 54:1755-1759, 2013
9. Sandström M, …, Lubberink M. Individualized dosimetry of kidneys and bone marrow in patients undergoing ^{177}Lu-DOTA-octreotide treatment. J Nucl Med 54:33-41, 2013
10. Van der Veldt AA, Lubberink M *et al*. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21:82-91, 2012
11. Van Assema DM, Lubberink M *et al.* Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 135:181-189, 2012
12. Harms HJ, … , Lubberink M. Parametric images of myocardial viability using a single [^{15}O]H_2O PET/CT scan. J Nucl Med 52:745-749, 2011
13. Harms HJ, … , Lubberink M. Automatic generation of absolute myocardial blood flow images using [^{15}O]H_2O and a clinical PET-CT scanner. Eur J Nucl Med Mol Imaging 38:930-939, 2011
14. Van der Veldt AA, … , Lubberink M. Quantitative parametric perfusion images using ^{15}O-water and a clinical PET/CT scanner: test-retest variability in lung cancer. J Nucl Med 2010 51:1684-1690, 2010
15. Lubberink M *et al.* Development of a tracer kinetic model of [^{11}C](*R*)-verapamil and its radioactive metabolites as PET tracer for p-glycoprotein function. J Cereb Blood Flow Metab 27:424-433, 2007

Academic merits

- Completed supervision of 6 PhD students as main supervisor and of 9 PhD students as co-supervisor.
- Ongoing supervision of 5 PhD students as main supervisor and of 5 PhD students as co-supervisor.